Moderna ‘laser-focused’ on AI, from clinical development to marketing: #CannesLions2023

When it comes to ar­ti­fi­cial in­tel­li­gence, Mod­er­na is all in.

Chief brand of­fi­cer Kate Cronin took the stage Tues­day at this year’s Cannes Li­ons In­ter­na­tion­al Fes­ti­val of Cre­ativ­i­ty to dis­cuss how the com­pa­ny is us­ing AI and oth­er dig­i­tal tools to dri­ve in­clu­siv­i­ty.

“We’re em­bed­ding AI in every­thing that we do,” she said in an in­ter­view with End­points News. 

That in­cludes re­cruit­ing for and con­duct­ing clin­i­cal tri­als, she said, ref­er­enc­ing the com­pa­ny’s land­mark COVE study eval­u­at­ing its first-gen­er­a­tion mR­NA-based Covid-19 vac­cine. Af­ter emerg­ing as an ear­ly leader in the race for a Covid vac­cine, Mod­er­na took a step back in 2020, slow­ing Phase III en­roll­ment to re­cruit a more di­verse tri­al pop­u­la­tion. Re­searchers used AI to learn the like­ly de­mo­graph­ics of cer­tain zip codes and pre­dict at­tri­tion to bet­ter dri­ve re­cruit­ment and re­ten­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN